There have been a number of small cap Israel companies in the cyber security space that have been taken over recently. I would not buy just on takeover speculation but I would be surprised if we were independent this time next year.
Figured time for new thread.
I guess it is possible that there is something wrong that we are not privy to, I don't think so, but have nothing to base that on.
It's funny we all want a lower price so we can get more then Mr. Market says here it is and we get nervous (believe me I am including myself). Based on past experience with this stock it is most likely a fund that for whatever reason does not want to be associated with us anymore. This change probably has nothing to do with our prospects. I've seen it in the past and expect it here.
We are an event driven stock, we are not being bought on fundamentals, no events investors lose patience. Nice to read that someone thinks we are worth $30 bucks a share but it is all based on conjecture. Conjecture will end with more deals and more scientific achievements.
In our case no news is bad news. That will change but I won't deny it , it is gut wrenching going though it.
By the way I think our CFO had a baby.
SBH, I very much appreciate your cultural reference to a certain type of poster, though I am a bit more of a Shakespearian my self so I tend to view it "As much ado about nothing".
Of course it is only a matter of time before the "Tempest" of another deal arrives and we have "Taming of the Shrew".
"Lay on, Anat"
Bananabb, currently operating cash flow does not cover distribution. Company doing all it can to maintain it including selling assets. Realistically there will be no increase in distributions for some time.
Could be a temporary decrease but my wishful thinking is NS will avoid. Basic assets still good.
Remember it goes both ways. If distribution decreased Nsh gets the harder hit. But lets hope they can get through the rough patch without a cut.
SBH, I have been a long term fan as to how cash has been handled by the company. Dikla only reenforced that feeling.
Ken, thanks for asking the question many of us wanted to ask. I thought the response was very positive. Also, if you are interested we gave two proteins to bioline. One of which is moving forward if you go on the Bioline website they have tab for pipline look at bioline 7060. There is a bit of information on the status.
Ultimately the call is just a call. At some point soon we will have our first commercial deal. Who knows how the stock will react when that happens but no matter what happens in the short term, this is a valuable company.
Keep in mind we have a valuation of about $200 MILLION, We have had no revenue for 10 years. We have nothing in clinical trials and we have not been endorsed by any financial house. This will all change during the next two years. If we are well funded and can keep dilution to a minimum. The valuation of our company will go up substantially.
What happens to the stock price today or anyday means nothing. The direction is up.
It seems baize gave us the $5 million. I read the 6-K that was released this morning and am having a bit of trouble understanding the new rules. Can't tell whether it is good or bad for us. Though someone kicking in 5 mill without getting it at a lower stock price is relatively good.
If CGEN does not publish in news release look on Edgar.
"It ain't necessarily so, No it ain't necessarily so, that down days are bad days and bad days are down days, No it ain't necessarily so".
A bit more Gershwin
Gilli, in the first quarter 2012 report the following was disclosed.
"The March 31, 2012 cash and cash related balance includes net proceeds of $3.1 million from the at-the-market sale during the quarter by the Company of 551,000 Compugen ordinary shares at an average price of $5.93 per share. These were the first sales made by the Company under its Shelf Registration Statement filed in January, 2011, and since March 31, 2012, an additional 100,000 shares were sold at an average price of $6.12 per share, with all sales made pursuant to a sales agreement entered into with Cantor Fitzgerald & Co. in August 2011. "
Looks like we are getting some under the table dilution of about 500K shares a quarter. I am not bent out of shape on this since I think it minimizes the number of shares needed to be sold and makes sure we stay liquid. Personally I am more comfortable with this approach then a formal stock sale. I think all around it is better for us. However, it should be remembered that it does have a dampening of our stock price. As you read the 20F it becomes obvious that the company will need more money if we are going to take our drugs into clincal trials. I am hoping that for the most part this will be funded by our preclinical deals but till we get one it is hard to say. Also when we do get a deal would not be surprised if we took the advantage of selling some more stock into the market just to insure our liquidity. Again i have no problem to drop a a couple of million shares if the price is over 10. I am not anxious to see small time dilution continue.
Again i recommend reading the 20F as i read it I had some concerns but then as I read what has been accomplished my concerns disapated.
I don't think the stock is cheap but it is in the right areas with the right technology. Looks like a great takeover candidate. You are right stock split is an excellent sign. Even though stock isn't cheap with cyber war at hand hard not to own it.